Switzerland's 4-Antibody AG has forged a new antibody discovery pact, this time with Human Genome Sciences on two undisclosed targets. No numbers were given for the collaboration, which follows on a similar pact that 4-Antibody struck with Boehringer in early 2010. "We're delighted to announce our second collaboration with an established pharmaceutical partner," says CEO Robert Burns. "Collaborations serve an important role in validating our Retrocyte Display technology platform and we're delighted that HGS wanted to enter into this multi-target collaboration with us. This adds an additional momentum to our other ongoing partnering activities." Release